Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 3

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

352

HTML

2454

Tables (1-3)

263

Sum=3069

Jan 21, 2009 (publication date) through Feb 18, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Articles

World J Gastroenterol. Jan 21, 2009; 15(3): 328-333
Published online Jan 21, 2009. doi: 10.3748/wjg.15.328

Table 1 Characteristics of the study population

Characteristics	Total group (n = 301)
Age¹ (yr)	48.27 ± 11.79
Gender (%, M/F)	57.5/42.5
Contamination mode (%)
Tranfusion	27.2
Drug-addict	26.9
Blood exposure accident	7.6
Others	38.2
Genotype (% with 1/2/3/4/5/ND)	35/11/18/8/2/26
Stage of fibrosis (% with stage 0/1/2/3/4/ND)	1/11/42/20/20/6
Type of treatment (%)
With IFNα	3.3
Peg-interferon	9.0
IFNα + ribavirin	27.2
Peg-interferon + ribavirin	60.4
Duration of treatment (mo)¹	7.91 ± 3.78
TSH before treatment (MIU/L)¹	1.54 ± 1.25
Positive antibodies before treatment
TPOAb	12/229
TGAb	8/227
TSHRAb	1/95

ND: Not determined.

¹mean ± SD.

Citation: Gelu-Simeon M, Burlaud A, Young J, Pelletier G, Buffet C. Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C. World J Gastroenterol 2009; 15(3): 328-333
URL: https://www.wjgnet.com/1007-9327/full/v15/i3/328.htm
DOI: https://dx.doi.org/10.3748/wjg.15.328